KIF20A

Diaccurate Announces the Appointment of Scott Filosi as EVEXTA BIOCEO and Corporate Name Change to Evexta Bio Scott Filosi brings more than 30 years of experience in market access and commercialization of innovative medicines at a global level. New name reflects the company's focus on its innovative portfolio of drug candidates that push the boundaries of precision oncology. Paris, France, November 6, 2023 - Diaccurate SA, a clinical-stage biotechnology company focused on developing targeted therapeutics in oncology, - announces the appointment of Scott Filosi as Chief Executive Officer (CEO), effective November 6, 2023. The company changes name to Evexta Bio, effective immediately. Dominique Bridon, former CEO, is appointed Chief Scientific Officer, and will remain as an executive and Board Member. Scott is an experienced executive leader with an outstanding track record in the pharmaceutical and biotechnology sector and as CEO. Scott brings more than 30 years of experience where he has put on the market more than 20 innovative medicines. Scott served as CEO of Luzsana Bio and Mirror Bio where he helped to advance key clinical programs, raise capital and advance strategic imperatives. Prior to his CEO roles, Scott was successively global Senior Vice President Market Access and Pricing and Chief Commercial Officer US for Merck KGaA successfully launching multiple oncology assets and indications. He brings diverse experience in sales, marketing, market access, pricing, operations and business development with organizations including UCB, J&J and Boehringer-Ingelheim. The Annual General Meeting also approved the change of company name to Evexta Bio. designed to better represent the company’s ability to advance rupitasertib through Phase 2/3 development, and to collaborate with partners for further development and commercialization. Along with the new name, the Company has adopted a new logo and is refreshing its corporate website to reflect the company’s strategy moving forward. Visit to learn more. Alain Chevallier, Chairman of the Board of Evexta Bio, commented:“The Board of Directors warmly welcomes Scott as the new CEO of Evexta Bio. Given his extensive international management experience in bringing successfully oncology drugs on the market, Scott is uniquely qualified to lead Evexta Bio's strategic development. He brings a unique set of skills, perspectives, and network to lead Evexta Bio into this new stage. I warmly thank Dominique for leading, during his tenure as CEO the shift of the company from a preclinical start-up to a late clinical stage biotech. I am pleased that he will continue to bring its tremendous scientific expertise to Evexta Bio as Chief Scientific Officer.” Scott Filosi, new CEO and Board Member of Evexta Bio,added: "I am thrilled to join Evexta Bio and its impressive team in a leadership position to advance its development strategy, and in particular, its clinical programs, both alone and in partnerships. I would like to thank Dominique for his dedication and look forward to building together on his achievements.” Dominique Bridon, PhD, CSO of Evexta Bio, said:“I am delighted to have Scott as the new CEO of Evexta Bio. With his impressive track record in the pharmaceutical and biotech industries, I believe Scott is the right person to lead the company through this important phase of development and partnering. I look forward to continuing to provide my scientific support to Evexta Bio.” ***** About Evexta Bio ( ) Evexta Bio, formerly Diaccurate, is a biopharmaceutical company exploring the new frontiers of oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications: Rupitasertib, formerly DIACC3010, an optimized S6K inhibitor with efficient AKT1/AKT3 control of feed-back loop. The oral anti-tumor agent is expected to enter phase 2/3 clinical trial in refractory ER+ HER2- metastatic breast cancer. EVX020, formerly DIACC2020, an antibody-drug conjugate program using a sole-in-class KIF20A kinesin inhibitor as payload in hematological and solid tumors. Founded by Truffle Capital, Evexta Bio has forged alliances with leaders in academia and industry, including CNRS, Paoli-Calmettes Institute (Marseille, France) and Merck KGaA (Darmstadt, Germany). The company is supported by seasoned management team, board of directors and medical advisory board. Contacts ATCG PARTNERS Marie Puvieux +33 (0)9 52 78 85 08 presse@atcg-partners.com Attachment PR in English

The DIACC2020 platform aims to develop a new generation of cytotoxic compounds to be conjugated to therapeutic antibodies The Program stems from the unique properties of its proprietary compound DIACC2010, developed by Diaccurate for the treatment of Acute Myeloid Leukemia Paris/Marseille, France, January5,2023 Diaccurate, a French biotechnology company specialized in the development of new therapies in oncology, today announced it received from Bpifrance a grant termed “Aide à l’Innovation” to support its DIACC2020 Program aiming to establish the preclinical proof-of-concept of its sole-in-class molecule DIACC2010 as a next-generation payload for ADCs, for the treatment of solid and hematologic tumors. About antibody-drug conjugates Antibody-drug conjugates (ADCs) are composed of a monoclonal antibody directed towards a tumoral target, coupled with a molecular linker to a potent cytotoxic drug. ADCs selectively deliver inside tumor cells the conjugated chemotherapy, improving its efficacy and tolerability pro This therapeutic class is now effectively used for the treatment of numerous cancers. However, the high toxicity of ADCs, for a large part mirroring that of their conjugated anticancer agent, limits their therapeutic index and clinical use. About DIACC2010 drug candidate and the DIACC2020 Program DIACC2010 is a sole-in-class selective inhibitor of kinesin KIF20A, a novel oncology target, involved in the functions of the Golgi apparatus and the control of cell division. DIACC2010 has shown potent preclinical antitumor efficacy in aggressive models of Acute Myeloid Leukemia (link to ASH poster) and solid tumors, including breast cancer. Its efficacy pro with the lack of toxicity towards normal cells strongly support the evaluation of DIACC2010 conjugated to therapeutic antibodies, for the development of a new generation of optimized ADCs. The DIACC2020 Program supported by Bpifrance is expected to demonstrate, in preclinical tumor models, that ADCs bearing DIACC2010 as payload are more efficacious and better tolerated than their referent ADC counterparts, thus improving their therapeutic index and broaden their potential indications. The workplan will run for 18 months up to the preclinical proof-of-concept in at least two models of human tumors. Preliminary efficacy and toxicity results will be available by the end of 2023 and will support potential license agreements with pharmaceutical companies. About Diaccurate Diaccurate explores the new frontiers of oncology in search of daring novel therapeutic approaches able to save lives. Now in the clinic, the French biotech is currently developing 3 proprietary therapeutics with novel mechanisms of action across several development programs: DIACC3010, an optimized S6K inhibitor with efficient AKT1/AKT3 control of feed-back loop. Oral antitumoral agent that crosses the blood-brain barrier and is expected to enter phase 2 clinical trial in refractory ER+ HER2- metastatic breast cancer and phase 1 trial in glioblastoma multiforme. DIACC2010, a sole-in-class KIF20A kinesin inhibitor, a novel oncology target. IV antitumoral agent with high selectivity towards cancer cells. DIACC2020, antibody drug conjugate using DIACC2010 as payload. Founded by Truffle Capital, Diaccurate has forged alliances with leaders in academia and industry, including CNRS, Paoli-Calmettes Institute (Marseille, France) and now Merck KGaA (Darmstadt, Germany). It relies on a high-level management team, board of directors and clinical advisory board. Diaccurate will attend JP Morgan Healthcare Conference in San Francisco CA, January 9-12, 2023. For more information, visit and follow @DiaccurateTx Contacts Dominique Bridon, CEO 33 (0)1 78 95 80 17 contact@diaccurate.com ATCG PARTNERS Marie Puvieux +33 (0)9 52 78 85 08 diaccurate@atcg-partners.com Attachment 220105 BPI DIACC2020_EN

A secretive French biotech has imported a drug from Germany’s Merck KGaA that will leapfrog the small company right into mid-stage testing against cancer. Diaccurate has in-licensed Merck KGaA’s M2698 — now dubbed DIACC3010 — a “PAM” inhibitor that is geared up for Phase II studies in both solid tumors and hematological malignancies, the French biotech said early Wednesday morning. Financial terms of the deal were not disclosed, but Merck KGaA said in a release it chose to work with Diaccurate after a “highly competitive selection process” that rewarded the biotech’s “strong scientific background.” Merck KGaA will become a shareholder in Diaccurate as part of the partnership, the companies said. DIACC3010 targets what’s known as the PAM signaling pathway — an umbrella designation covering the PI3K, AKT and mTOR kinases — and has shown preclinical and early human efficacy in crossing the blood-brain barrier, potentially offering benefit in neurological malignancies, Diaccurate said. The drug itself is a dual inhibitor specifically targeting AKT1/3 and p70S6, which Diaccurate thinks could have effect on a broad range of solid tumors and hematologic malignancies. DIACC3010 does have some clinical data to show, but not much to get excited about on the monotherapy front. In a 101-patient Phase I test, the drug posted a 27.4% stable disease rate as a monotherapy in solid tumors with no partial responses reported. Two breast cancer patients in separate combo regimen arms posted partial responses but those data weren’t powered for efficacy. Meanwhile, the drug was mostly well tolerated on the safety front. Diaccurate’s clinical plans, it says, are two-pronged: The biotech plans to launch a Phase II solid tumor program initially focused around triple-negative breast cancer and gastric cancers — both of which exhibit a high prevalence of PAM mutations — as well as blood cancers in which the PI3K pathways play a major role (potentially relapsed/refractory B cell and T cell lymphomas). Both of those studies are expected to launch in the second half of 2022, and Diaccurate said “further details on the clinical program will be provided in due time.” “Diaccurate is laying the foundations of a successful modern biotech company with a new highly specialized portfolio approach,” co-founder Philippe Pouletty said in a statement. “This is an exciting agreement that will take the Company to the next level, bringing the best of medical science innovation to patients.” Diaccurate is still a mostly unknown name: The biotech was co-founded by Paris-based venture firm Truffle Capital and is being advised by Tasuku Honjo, a winner of the Nobel Prize in Medicine in 2018. The company sports two other candidates — a KIF20A inhibitor chemotherapy and a CD4 immunotherapy — and said in a release it has existing partnerships with Merck KGaA, France’s Institut Pasteur and the Institut Paoli-Calmettes.